DORA Schedule IV-to-V Reclassification: Access Win Confirmed, Full Descheduling Gap Remains

DEA Proposes Reclassifying Idorsia's DORA to Schedule V

Idorsia Ltd announced that the US Drug Enforcement Administration (DEA) will publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs), including Idorsia's QUVIVIQ (daridorexant), from Schedule IV to Schedule V under the Controlled Substances Act (CSA). This proposal follows a scientific and medical evaluation by HHS and the DEA's own eight-factor analysis, which concluded that DORAs "do not produce physical or psychological dependence." Idorsia views this reclassification to the least restrictive Schedule V as an important first step, expecting it to enhance patient access in the US, although the company believes available evidence supports full descheduling. The proposed rule will be open for public comment for 30 days.

• The US Drug Enforcement Administration (DEA) is set to publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V under the Controlled Substances Act (CSA). This decision is based on a scientific and medical evaluation and scheduling recommendation from HHS, followed by the DEA's own eight-factor analysis, which determined that DORAs do not produce physical or psychological dependence.
• Idorsia's Chairman and interim CEO, Jean-Paul Clozel, MD, welcomed the proposed reclassification to Schedule V as a crucial initial step, acknowledging the favorable profile of daridorexant compared to traditional sedative-hypnotics. While Idorsia believes the evidence supports full descheduling, they will analyze the proposal and provide comments, hoping the reduced restrictions will improve patient access to the DORA class.
• QUVIVIQ (daridorexant), Idorsia's dual orexin receptor antagonist, is currently approved in the United States for the treatment of adult patients with chronic insomnia characterized by difficulties with sleep onset and/or sleep maintenance. The reclassification aims to make this and other DORAs more accessible to patients by moving them to the lowest controlled substance schedule.

Daridorexant's Favorable Profile Drives DEA Reclassification to Schedule V

Daridorexant has demonstrated a consistently favorable safety and tolerability profile across diverse patient populations, dose levels, and treatment durations in published clinical studies. Notably, the absence of abuse-related signals and rebound phenomena distinguishes it from older sedative-hypnotic agents and underpins its regulatory reclassification.

• Low and placebo-comparable adverse event incidence: In a 40-week extension study (N = 801), treatment-emergent adverse event (TEAE) rates were similar across all dose groups (35–40%) and aligned with placebo. The most commonly reported events were nasopharyngitis and headache. In Chinese patients, TEAE rates during double-blind treatment were comparable between daridorexant and placebo (21.6% vs. 18.4%), with no notable safety signals identified.

• No withdrawal, rebound insomnia, or next-morning residual sedation: Across multiple studies, daridorexant did not induce next-morning sleepiness, withdrawal-related symptoms, or rebound insomnia upon discontinuation — a clinically meaningful differentiation from traditional sedative-hypnotics.

• Favorable profile in older adults (≥65 years): Overall adverse event incidence was comparable to placebo, with fewer falls reported on daridorexant than placebo. No cases of narcolepsy, cataplexy, or complex sleep behavior were observed, and only one case of sleep paralysis was reported. Residual next-morning effects were not increased, even at the 50 mg dose.

• Long-term Japanese population data: In a 52-week open-label study in Japanese patients, TEAEs occurred in 74% (50 mg) and 58% (25 mg) of participants, with no serious drug-related TEAEs reported. Five adjudicated adverse events of special interest were recorded: excessive daytime sleepiness (n = 3), sleep paralysis (n = 1), and nightmare (n = 1). Both doses maintained improvements in next-morning sleepiness throughout the study duration.

• Nonclinical abuse potential assessment: Rat studies demonstrated no reinforcing effects, dissimilarity to zolpidem in drug discrimination paradigms, and no withdrawal signs upon discontinuation indicative of physical dependence — collectively supporting a low abuse liability profile in humans.

• Pharmacokinetic and dosing considerations: Dose reduction to 25 mg is recommended in moderate hepatic impairment, with use contraindicated in severe hepatic impairment. Race, body size, and mild-to-moderate renal impairment did not meaningfully affect pharmacokinetic or pharmacodynamic parameters. Caution is warranted with strong CYP3A4 inhibitors and inducers given daridorexant's hepatic CYP3A4-mediated metabolism.

Addressing Insomnia Treatment Limitations Through Enhanced Daridorexant Access

Current treatment approaches for chronic insomnia remain hampered by a combination of limited accessibility, suboptimal efficacy, and clinically significant safety liabilities. Across both non-pharmacological and pharmacological options, no single strategy consistently addresses the full spectrum of sleep onset and sleep maintenance difficulties without meaningful trade-offs. These gaps underscore a persistent unmet need for treatment alternatives with more favourable benefit-risk profiles.

• CBT-I accessibility and efficacy gaps: While cognitive behavioural therapy for insomnia (CBT-I) is a first-line recommendation, its real-world utility is constrained by high dropout rates, waiting list delays for face-to-face delivery, and inefficacy in approximately 30% of patients. A further proportion of individuals do not engage with healthcare services at all, contributing to a recognised treatment gap.

• Benzodiazepine hypnotics — safety and dependence liabilities: This class is associated with altered sleep architecture, psychomotor and memory impairment, next-day "hangover" effects, rebound insomnia, tolerance, dependence, abuse potential, respiratory depression, and an elevated risk of falls and hip fractures — particularly in elderly patients.

• Z-drug limitations across efficacy and safety dimensions: Non-benzodiazepine hypnotics (zolpidem, zopiclone, zaleplon) carry risks of anterograde amnesia, complex sleep behaviours (sleepwalking, sleep-driving, hallucinations), and psychomotor impairment. Patients taking zopiclone or zolpidem face more than double the risk of motor vehicle collisions compared to unexposed individuals. Agents with rapid onset and short half-lives also demonstrate limited efficacy for sleep maintenance, while abuse and withdrawal reactions have been reported with zolpidem.

• Residual next-day impairment as a cross-class concern: A consistent liability across pharmacological options is next-day residual sedation, which can impair memory, driving ability, and psychomotor performance. Disturbed body balance and standing steadiness following nocturnal or early-morning awakening represent particular hazards, especially in older populations.

• Inconsistent efficacy across insomnia symptom profiles: Approved pharmacological treatments do not reliably address both sleep onset and sleep maintenance difficulties, and insomnia symptoms themselves often shift unpredictably over time between these presentations — further limiting the durability and adaptability of existing regimens.

• Unfavourable risk-benefit balance in vulnerable populations: The cumulative safety burden of current pharmacological options — particularly falls, fractures, and motor vehicle accidents — may render the risk-benefit calculation unfavourable in elderly patients, precisely the population with the highest insomnia prevalence.

Meeting Unmet Needs in Chronic Insomnia with DORA Class Access

Chronic insomnia remains a condition with substantial unmet need across several patient populations, and the dual orexin receptor antagonist (DORA) class has emerged as a focal point for addressing these gaps. Evidence from recent literature highlights both demographic and comorbidity-defined subgroups where current treatment options remain inadequate or insufficiently studied.

• Psychiatric comorbid populations: Patients with insomnia comorbid with depression, bipolar disorder, or substance use disorders represent a significant unmet need. DORAs — specifically lemborexant and suvorexant — have been investigated in these populations, with early evidence suggesting comparable efficacy and safety to their use in primary insomnia, though data remain limited to a small number of studies.

• Diverse ethnic populations: A Phase III clinical trial evaluating daridorexant 50 mg specifically in Chinese patients with insomnia disorder demonstrated significant improvements in both objective and subjective sleep outcomes alongside a favorable safety profile, underscoring the need for ethnically representative evidence bases to support broader clinical adoption.

• Patients with medical comorbidities: Specific disease populations carry a disproportionate sleep burden. Patients with systemic lupus erythematosus (SLE) exhibit worse sleep maintenance parameters and higher perceived stress versus healthy controls, with daily glucocorticoid dose independently associated with sleep maintenance impairment — a pattern consistent with normal sleep duration insomnia. Separately, long COVID patients demonstrate a high neuropsychiatric symptom burden, including insomnia in approximately 58% of cases, alongside subjective cognitive impairment and headache.

• Patients seeking non-pharmacological options: For individuals with comorbid depression and insomnia who are unable or unwilling to use pharmacotherapy, non-pharmacological interventions are being actively explored, reflecting an additional unmet need that extends beyond the DORA class itself.

Daridorexant's Reclassification: A Strategic Win for Insomnia Care

The proposed reclassification of dual orexin receptor antagonists (DORAs), specifically Idorsia's daridorexant (QUVIVIQ), from Schedule IV to Schedule V by the US Drug Enforcement Administration (DEA) represents a pivotal moment for insomnia treatment. This decision, stemming from a scientific and medical evaluation concluding that DORAs 'do not produce physical or psychological dependence,' underscores a growing understanding of these agents' unique profile.

Unlike traditional sedative-hypnotics that primarily induce sedation, DORAs work by inhibiting wakefulness, offering a distinct mechanism of action. This difference is crucial, as long-term studies of daridorexant have demonstrated sustained improvements in sleep and daytime functioning over 12 months, without evidence of withdrawal symptoms or rebound insomnia upon discontinuation. For patients struggling with chronic insomnia, a condition often undertreated and linked to other health issues, improved access to such a therapy could significantly enhance outcomes.

Strategically, this reclassification offers a substantial advantage. By reducing the regulatory burden associated with Schedule IV drugs, daridorexant could see increased prescribing rates and broader patient access. This move positions it more competitively against other Schedule IV insomnia medications, particularly for long-term use where concerns about dependence are paramount. However, it is important to acknowledge that while the DEA's finding focuses on dependence, some studies on other DORAs have indicated abuse potential similar to existing Schedule IV drugs in specific populations. Additionally, DORAs are associated with a higher risk of certain adverse events, such as excessive daytime sleepiness and sleep paralysis, which clinicians and patients must consider. Idorsia's ambition for full descheduling suggests a continued push to further streamline access, indicating that the journey to fully integrate DORAs into mainstream insomnia management is still evolving.